Skip to main content
placeholder image

Cartilage Tissue Engineering Using Stem Cells and Bioprinting Technology-Barriers to Clinical Translation

Journal Article


Abstract


  • There is no long-term treatment strategy for young and active patients with cartilage

    defects. Early and effective joint preserving treatments in these patients are crucial

    in preventing the development of osteoarthritis. Tissue engineering over the past few

    decades has presented hope in overcoming the issues involved with current treatment

    strategies. Novel advances in 3D bioprinting technology have promoted more focus on

    efficient delivery of engineered tissue constructs. There have been promising in-vitro

    studies and several animal studies looking at 3D bioprinting of engineered cartilage tissue.

    However, to date there are still no human clinical trials using 3D printed engineered

    cartilage tissue. This review begins with discussion surrounding the difficulties with

    articular cartilage repair and the limitations of current clinical management options which

    have led to research in cartilage tissue engineering. Next, the major barriers in each

    of the 4 components of cartilage tissue engineering; cells, scaffolds, chemical, and

    physical stimulation will be reviewed. Strategies that may overcome these barriers will

    be discussed. Finally, we will discuss the barriers surrounding intraoperative delivery of

    engineered tissue constructs and possible solutions.

Authors


  •   Francis, Sam (external author)
  •   Di Bella, Claudia (external author)
  •   Wallace, Gordon G.
  •   Choong, Peter (external author)

Publication Date


  • 2018

Citation


  • Francis, S. L., Di Bella, C., Wallace, G. G. & Choong, P. F. M. (2018). Cartilage Tissue Engineering Using Stem Cells and Bioprinting Technology-Barriers to Clinical Translation. Frontiers in Surgery, 5 70-1-70-12.

Start Page


  • 70-1

End Page


  • 70-12

Volume


  • 5

Place Of Publication


  • Switzerland

Abstract


  • There is no long-term treatment strategy for young and active patients with cartilage

    defects. Early and effective joint preserving treatments in these patients are crucial

    in preventing the development of osteoarthritis. Tissue engineering over the past few

    decades has presented hope in overcoming the issues involved with current treatment

    strategies. Novel advances in 3D bioprinting technology have promoted more focus on

    efficient delivery of engineered tissue constructs. There have been promising in-vitro

    studies and several animal studies looking at 3D bioprinting of engineered cartilage tissue.

    However, to date there are still no human clinical trials using 3D printed engineered

    cartilage tissue. This review begins with discussion surrounding the difficulties with

    articular cartilage repair and the limitations of current clinical management options which

    have led to research in cartilage tissue engineering. Next, the major barriers in each

    of the 4 components of cartilage tissue engineering; cells, scaffolds, chemical, and

    physical stimulation will be reviewed. Strategies that may overcome these barriers will

    be discussed. Finally, we will discuss the barriers surrounding intraoperative delivery of

    engineered tissue constructs and possible solutions.

Authors


  •   Francis, Sam (external author)
  •   Di Bella, Claudia (external author)
  •   Wallace, Gordon G.
  •   Choong, Peter (external author)

Publication Date


  • 2018

Citation


  • Francis, S. L., Di Bella, C., Wallace, G. G. & Choong, P. F. M. (2018). Cartilage Tissue Engineering Using Stem Cells and Bioprinting Technology-Barriers to Clinical Translation. Frontiers in Surgery, 5 70-1-70-12.

Start Page


  • 70-1

End Page


  • 70-12

Volume


  • 5

Place Of Publication


  • Switzerland